Evaluation of Cognitive Function of Patients With Sunitinib or Sorafenib
Evaluation of Cognitive Function of Patients Treated With Sunitinib or Sorafenib
Patients with advanced kidney cancer or GIST (Gastro Intestinal Stromal Tumor: this is a tumor of the intestines) may be eligible for treatment with one of the following drugs: sunitinib (Sutent ®) or sorafenib (Nexavar ®). These drugs inhibit blood vessel formation in cancer cells. These cancer cells are hampered in their growth. To enlarge the investigators knowledge on the effects and side effects of these two medicines, in the University Medical Center St. Radboud lot of research is done. This study is a part of that.
Patients receiving sunitinib or sorafenib tell sometimes that they feel that they are less able to concentrate, that their memory is not working properly or that they are less able to imagine a solution to a complex problem . Perhaps you recognize these symptoms as well. In how many of the patients this occurs, how severe the symptoms are and how it is caused, is still unknown.
The goal of this research is to examine how memory, concentration and knowledge processing works in patients using sorafenib or sunitinib. With the research the investigators hope to get answers to the following questions:
- How common are problems with memory, concentration and processing of knowledge in patients receiving the drug sunitinib or sorafenib?
- What are the problems of memory, concentration and processing of knowledge in the use of sunitinib or sorafenib?
- What could be the cause of the problems that patients experience from memory, concentration and processing of knowledge in the use of sunitinib or sorafenib?
- Is there a link between problems with memory, concentration and processing of knowledge and also experiences of fatigue or mood of a patient?
研究概览
详细说明
研究类型
注册 (预期的)
联系人和位置
学习地点
-
-
Gelderland
-
Nijmegen、Gelderland、荷兰、6500 HB
- University Medical Centre Nijmegen
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion Criteria:
- Patients:
- patients with metastatic renal cell cancer or GIST who are on treatment with Sunitinib or Sorafenib for ≥ 8 weeks
- Karnofsky score > 70%
- age > 18 year.
- written informed consent for study
Patient controls selection
- patients with metastatic renal cell cancer or GIST who aren't treated yet (only interferon alfa or interleukine 2 treatment is allowed when > 12 months ago.
- Karnofsky score > 70%
- age > 18 year.
- written informed consent for study
Exclusion Criteria:
- Patients:
- contra-indications for treatment with Sunitinib or Sorafenib
- patients who do not speak or write the Dutch language adequately
- known brain metastasis
- use of psychiatric or anti-epileptic medication
- known cognitive disorders unrelated to diagnosis or medication use
- radiotherapy on the brain at any time in the past
- systemic chemotherapy
- in the last 12 months interferon alfa or interleukin-2 treatment
- operation in the last 3 months
- Stroke/TIA (transient ischaemic attack)
Patient controls section:
- patients who do not speak or write the Dutch language adequately
- known brain metastasis
- use of psychiatric or anti-epileptic medication
- known cognitive disorders unrelated to diagnosis or medication use
- radiotherapy on the brain at any time in the past
- systemic chemotherapy
- in the last 12 months interferon alfa or interleukin-2 treatment
- operation in the last 3 months
- stroke/TIA (transient ischaemic attack)
学习计划
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
|---|
|
metastatic Renal Cell Carcinoma without treatment
patients with metastasized RCC who did not receive treatment
|
|
mRCC with treatment
patients with metastastic renal cell cancer or GIST who are on treatment with Sunitinib or Sorafenib for ≥ 8 weeks |
合作者和调查者
出版物和有用的链接
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.